Molecure (Group)

https://www.molecure.com

LinkedIn: https://www.linkedin.com/company/molecure-sa

OncoArendi Therapeutics SA (WSE:OAT) is a Polish innovative biotechnology company specializing in research, development and commercialization of innovative small molecule drugs for treatment of respiratory diseases and cancer. Researchers at OncoArendi study the role of chitinases and chitinase-like-proteins that provide multiple opportunities for therapeutic interventions. OncoArendi currently has a platform of distinct small molecule programs targeting this classes of proteins, which may have potential utility in diverse inflammatory and fibrotic diseases of high unmet medical need. OncoArendi is also focusing on the development of small molecule immune-modulators targeting a key enzyme involved in amino acid metabolism that allows tumor cells to hamper anti-tumor immunity and to avoid immune surveillance. OncoArendi Therapeutics' business model is based on the discovery and development of first-in class or best-in-class small molecules, and then outlicensing its assets to larger pharmaceutical and biotechnology companies. The company has been listed on the WSE main market since April 2018. *

	Start	2022-03-28 renamed
	Predecessor	OncoArendi (Group)
	Industry	cancer immunotherapy (immuno-oncology, I-O)
	Industry 2	immunotherapy
	Person	Szumowski, Marcin (OncoArendi 202011 CEO)
	Person 2	Beuzen, Nicolas (OncoArendi 202011 Director Business Development)

	Region	Warszawa (Warsaw)
	Country	Poland
	Street	101 Zwirki i Wigury
	City	02089 Warszawa
	Tel	+48-22-552-6724
		Address record changed: 2024-01-05

Basic data	Employees	n. a.
	Currency	PLN
	Annual sales	1,640,000 (income, operating, consolidated (2022) 2022-12-31)
	Profit	-15,260,000 (2022-12-31)
	Cash	66,000,000 (2022-12-31)

		* Document for »About Section«: Galapagos N.V.. (11/5/20). "Press Release: OncoArendi and Galapagos Enter into Exclusive Collaboration on Chitinase Inhibitors in Fibrosis". Mechelen & Warsaw.

		Record changed: 2023-07-10